Showing 464 results
-
Media Release /- 82% of patients with pancreatic neuroendocrine tumors (NET) experienced clinical benefit when treated with daily RAD001 and monthly Sandostatin LAR Depot- 77% of patients with pancreatic NET…
-
Media Release /Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic idiopathic urticaria (CIU) in patients with an inadequate response to H1 anthistamines1 Currently…
-
Media Release /Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of approximately 17…
-
Media Release /- Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved for adult patients with active ankylosing spondylitis (AS) and psoriatic arthritis (PsA)- Approvals for both indications…
-
Media Release /Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,2 62% of patients…
-
Media Release /Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable (1)Patients had a 65% chance of being relapse-free…
-
Media Release /- STEP Program is available to US-based nonprofit patient advocacy organizations- Recipients will receive funding to support proposals that demonstrate innovation in awareness and education, self-…
-
Media Release /Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0) disease, as well as between…
-
Media Release /Addition of Kisqali® (ribociclib) to endocrine therapy (ET) demonstrated a 28% risk reduction in invasive disease-free survival (iDFS) in subgroup of patients with node-negative (N0) disease…
-
Media Release /If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant…
